Reshaping the Landscape of Cancer Drug Discovery and Development By Dr Paolo Paoletti The landscape of cancer drug discovery and development is shifting, adjusting and reshaping itself in response to the huge rush of scientific knowledge which has come to the fore over the past few decades. Read More
Designing animal models for evaluation of therapeutic and vaccine candidates for emerging and biodefence-related pathogens By Dr Colleen Jonsson and Dr Peter Silvera While a number of promising drug therapies and vaccines have been identified for safeguarding bioterrorism organisms and diseases, further development requires well characterised animal models… Read More
Molecular Diagnostics in Drug Development – The changing face of pharmaceutical discovery By Dr Berwyn Clarke Clinical drug development is moving into an era where high technology new diagnostics are key to the development of the majority of new drugs. Markers are now available that… Read More
Automated Biobanking – The next big step for biorespositories By Dr John Comley As a significant proportion of the many newly established national, regional and disease-specific biobanks or biorespositories contemplate how they will enable enhanced sample integrity, tracking and audit trail, there has never been a more… Read More
Tools for Target Identification, Validation and Biomarker Discovery By Dr Paul Denny-Gouldson As automation in the drug discovery arena increases then so does the amount and complexity of the data. We discuss an emerging solution that now integrates various technologies to provide a scientific data intelligence tool… Read More
Enabling Collaborative Science via the Integration of Analytical Data into Organisational Systems By Mark Bayliss The storage of data drawn from the analytical process has for years been the stumbling block in the overall ‘knowledge management’ of the discovery process. This article argues that current… Read More
Changing the Model for Lab Equipment Maintenance and Asset Management By Martin Long A large section of the Pharmaceutical, Biotech and supporting industries are currently driving aggressive cost-saving initiatives throughout their operations to remain competitive, and deliver shareholder value. One such area is the cost associated… Read More
Personalised Medicine – Technological innovation and patient empowerment or exuberant hyperbole? By Adam W. Culbertson, Dr Stephen J. Valentine and Dr Stephen Naylor The current paradigm of modern healthcare focuses on patient symptoms, subsequent diagnosis and corresponding treatment of the specific disease(s). Escalating healthcare costs and a… Read More
The evolving world of drug discovery data integration in the pharmaceutical industry Dr David Sedlock The world of drug discovery has been impacted significantly by an ever evolving use of computer systems during the past 25 years with the greatest change occurring during the past 10 years… Read More
Establishment of an open access compound management facility By David Camp This article covers the establishment of an open access compound management facility in Australia to stimulate applied, basic and translational biomedical research. The paradigm for probing biological processes and drug discovery via small molecules has… Read More
By Dr Jean-Luc Vanderheyden As the experience and advances in Positron Emission Tomography (PET) imaging grows, so does the belief that this technology can have a key role to play in ushering in an era of personalised medicine while also offering an enormous contribution in… Read More
Serial vs Direct Dilution – Time to apply new thinking to IC50 determination and dose-response analysis? By Dr John Comley The serial dilution method is standard practice in the preparation of doseresponse series for IC50 determination. However, it is well recognised that inadequacies in the liquid handling… Read More
By Anthony Rosenberg Partnering and licensing have become paramount in a pharmaceutical industry that is under inordinate pressure to fill pipelines and increase the number of approved new molecular entities. This article discusses how Novartis has gone about addressing this issue. There is a great deal… Read More
Lean Thinking for Drug Discovery – Better Productivity for Pharma By Dr Edward W. Petrillo Success in drug discovery controls the success of the pharmaceutical enterprise. The molecular structure of every drug candidate, and the body of knowledge that will guide its use in the treatment of disease,… Read More
India – Global pharmaceutical R&D powerhouse or contract research workshop? By Dr Matthew Howard In response to the ever-increasing costs of drug discovery and development, pharmaceutical industry leaders must constantly seek to increase productivity while simultaneously reducing costs and maintaining quality. Globalisation of drug discovery may… Read More
Sharing Risks and Rewards – Basis for a turnkey pharma-biotech alliance in osteoarthritis Dr Andre Hoekema In June 2006, Galapagos and GlaxoSmithKline’s Center of Excellence for External Drug Discovery (CEEDD) formed a multi-year worldwide alliance to discover and develop novel drugs for osteoarthritis. The focus of… Read More